This week, Xenikos announced the first patient dosed in their Phase 3 study for T-Guard, a candidate for the treatment of severe acute graft-versus-host disease (aGVHD).
Learn more in their press release.
Related news items
Successful matchmaking at Radboudumc Investment Day7 October 2022
On the 5th of October, over 100 scientists, investors and entrepreneurs came together at the second Radboudumc Investment Day, jointly hosted by Radboudumc, Oost NL and Briskr.read more